Two of the cell lines (VMCUB1 and SW1710) most resistant to cisplatin express a low level of HRAS, and the other two cell lines (HT1376 and 5637) with less resistance to cisplatin express a high level of HRAS (Figure 1D and Figure 2C), suggesting that the TP53 mutant bladder cancer cells with a higher expression level of HRAS were less resistant to cisplatin, although the elevated HRAS expression had no beneficial effect in all of the cisplatin-treated bladder cancer cell lines stored in the database despite the TP53 genotype (Figure 1C). Here, HRAS is linked to urinary bladder carcinoma.